1887

Journal of General Virology header logo

Volume 101, Issue 8

Induction of adaptive immune responses against antigens incorporated within the capsid of simian virus 40 Free

Abstract

Simian virus 40 (SV40) is a monkey polyomavirus. The capsid structure is icosahedral and comprises VP1 units that measure 45 nm in diameter. Five SV40 VP1 molecules form one pentamer subunit, and a single icosahedral subunit comprises 72 pentamers; a single SV40 VP1 capsid comprises 360 SV40 VP1 molecules. In a previous study, we showed that an influenza A virus matrix protein 1 (M1) CTL epitope inserted within SV40 virus-like particles (VLPs) induced cytotoxic T lymphocytes (CTLs) without the need for an adjuvant. Here, to address whether SV40 VLPs induce adaptive immune responses against VLP-incorporated antigens, we prepared SV40 VLPs containing M1 or chicken ovalbumin (OVA). This was done by fusing M1 or OVA with the carboxyl terminus of SV40 VP2 and co-expressing them with SV40 VP1 in insect cells using a baculovirus vector. Intraperitoneal (i.p.) or intranasal administration of SV40 VLPs incorporating M1 induced the production of CTLs specific for the M1 epitope without the requirement for adjuvant. The production of antibodies against SV40 VLPs was also induced by i.p. administration of SV40 VLPs in the absence of adjuvant. Finally, the administration of SV40 VLPs incorporating OVA induced anti-OVA antibodies in the absence of adjuvant; in addition, the level of antibody production was comparable with that after i.p. administration of OVA plus alum adjuvant. These results suggest that the SV40 capsid incorporating foreign antigens can be used as a vaccine platform to induce adaptive immune responses without the need for adjuvant.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): adjuvant , antibody production , cytotoxic T lymphocyte , simian virus 40 , vaccine and virus-like particles
Funding
This study was supported by the:
  • the 44rd Science Research Promotion Fund by the Promotion and Mutual Aid Corporation for Private Schools of Japan
    • Principle Award Recipient: Masaaki Kawano
  • the 43rd Science Research Promotion Fund by the Promotion and Mutual Aid Corporation for Private Schools of Japan
    • Principle Award Recipient: Masaaki Kawano
  • a Grant-in-Aid for Scientific Research (S) from the Japanese Society for the Promotion of Science (Award 17H06112)
    • Principle Award Recipient: Hiroshi Handa
  • a Grant-in-Aid for Scientific Research (C) from Japanese Society for the Promotion of Science (Award 19K08887)
    • Principle Award Recipient: Sho Matsushita
  • a Grant-in-Aid for Challenging Exploratory Research from the Japanese Society for the Promotion of Science (Award 15K15375)
    • Principle Award Recipient: Sho Matsushita
  • a Grant-in-Aid for Scientific Research (C) from the Japanese Society for the Promotion of Science (Award 18K06631)
    • Principle Award Recipient: Masanori Matsui
  • a Grant-in-Aid for Scientific Research (C) from the Japanese Society for the Promotion of Science, (Award 19K07201)
    • Principle Award Recipient: Masaaki Kawano
  • a Grant-in-Aid for Scientific Research (C) from Japanese Society for the Promotion of Science (Award 16K08412)
    • Principle Award Recipient: Masaaki Kawano
© 2020 The Authors
Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.001445
2020-06-05
2024-04-24
Loading full text...

Full text loading...

/deliver/fulltext/jgv/101/8/853.html?itemId=/content/journal/jgv/10.1099/jgv.0.001445&mimeType=html&fmt=ahah

References

  1. Valenzuela P, Medina A, Rutter WJ, Ammerer G, Hall BD. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature 1982; 298:347–350 [View Article][PubMed]
     [Google Scholar]
  2. McAleer WJ, Buynak EB, Maigetter RZ, Wampler DE, Miller WJ et al. Human hepatitis B vaccine from recombinant yeast. Nature 1984; 307:178–180 [View Article][PubMed]
     [Google Scholar]
  3. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A 1992; 89:12180–12184 [View Article][PubMed]
     [Google Scholar]
  4. Delpeyroux F, Chenciner N, Lim A, Malpièce Y, Blondel B et al. A poliovirus neutralization epitope expressed on hybrid hepatitis B surface antigen particles. Science 1986; 233:472–475 [View Article][PubMed]
     [Google Scholar]
  5. Greenstone HL, Nieland JD, de Visser KE, De Bruijn ML, Kirnbauer R et al. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc Natl Acad Sci U S A 1998; 95:1800–1805 [View Article][PubMed]
     [Google Scholar]
  6. Liddington RC, Yan Y, Moulai J, Sahli R, Benjamin TL et al. Structure of simian virus 40 at 3.8-A resolution. Nature 1991; 354:278–284 [View Article][PubMed]
     [Google Scholar]
  7. Yan Y, Stehle T, Liddington RC, Zhao H, Harrison SC. Structure determination of simian virus 40 and murine polyomavirus by a combination of 30-fold and 5-fold electron-density averaging. Structure 1996; 4:157–164 [View Article][PubMed]
     [Google Scholar]
  8. Salunke DM, Caspar DL, Garcea RL. Self-Assembly of purified polyomavirus capsid protein VP1. Cell 1986; 46:895–904 [View Article][PubMed]
     [Google Scholar]
  9. Garcea RL, Salunke DM, Caspar DL. Site-Directed mutation affecting polyomavirus capsid self-assembly in vitro. Nature 1987; 329:86–87 [View Article][PubMed]
     [Google Scholar]
  10. Ishizu KI, Watanabe H, Han SI, Kanesashi SN, Hoque M et al. Roles of disulfide linkage and calcium ion-mediated interactions in assembly and disassembly of virus-like particles composed of simian virus 40 VP1 capsid protein. J Virol 2001; 75:61–72 [View Article][PubMed]
     [Google Scholar]
  11. Kanesashi S-N, Ishizu K-I, Kawano M-A, Han S-I, Tomita S et al. Simian virus 40 VP1 capsid protein forms polymorphic assemblies in vitro. J Gen Virol 2003; 84:1899–1905 [View Article][PubMed]
     [Google Scholar]
  12. Kawano M-aki, Inoue T, Tsukamoto H, Takaya T, Enomoto T et al. The VP2/VP3 minor capsid protein of simian virus 40 promotes the in vitro assembly of the major capsid protein VP1 into particles. J Biol Chem 2006; 281:10164–10173 [View Article][PubMed]
     [Google Scholar]
  13. Tsukamoto H, Kawano M-A, Inoue T, Enomoto T, Takahashi R-U et al. Evidence that SV40 VP1-DNA interactions contribute to the assembly of 40-nm spherical viral particles. Genes Cells 2007; 12:1267–1279 [View Article][PubMed]
     [Google Scholar]
  14. Enomoto T, Kukimoto I, Kawano M-aki, Yamaguchi Y, Berk AJ et al. In vitro reconstitution of SV40 particles that are composed of VP1/2/3 capsid proteins and nucleosomal DNA and direct efficient gene transfer. Virology 2011; 420:1–9 [View Article][PubMed]
     [Google Scholar]
  15. Inoue T, Kawano M-aki, Takahashi R-u, Tsukamoto H, Enomoto T et al. Engineering of SV40-based nano-capsules for delivery of heterologous proteins as fusions with the minor capsid proteins VP2/3. J Biotechnol 2008; 134:181–192 [View Article][PubMed]
     [Google Scholar]
  16. Kitai Y, Fukuda H, Enomoto T, Asakawa Y, Suzuki T et al. Cell selective targeting of a simian virus 40 virus-like particle conjugated to epidermal growth factor. J Biotechnol 2011; 155:251–256 [View Article][PubMed]
     [Google Scholar]
  17. Enomoto T, Kawano M, Fukuda H, Sawada W, Inoue T et al. Viral protein-coating of magnetic nanoparticles using simian virus 40 VP1. J Biotechnol 2013; 167:8–15 [View Article][PubMed]
     [Google Scholar]
  18. Kawano M, Doi K, Fukuda H, Kita Y, Imai K et al. SV40 VP1 major capsid protein in its self-assembled form allows VP1 pentamers to coat various types of artificial beads in vitro regardless of their sizes and shapes. Biotechnol Rep 2015; 5:105–111 [View Article][PubMed]
     [Google Scholar]
  19. Takahashi R-u, Kanesashi S-nosuke, Inoue T, Enomoto T, Kawano M-aki et al. Presentation of functional foreign peptides on the surface of SV40 virus-like particles. J Biotechnol 2008; 135:385–392 [View Article][PubMed]
     [Google Scholar]
  20. Kawano M, Morikawa K, Suda T, Ohno N, Matsushita S et al. Chimeric SV40 virus-like particles induce specific cytotoxicity and protective immunity against influenza A virus without the need of adjuvants. Virology 2014; 448:159–167 [View Article][PubMed]
     [Google Scholar]
  21. Gotch F, McMichael A, Smith G, Moss B. Identification of viral molecules recognized by influenza-specific human cytotoxic T lymphocytes. J Exp Med 1987; 165:408–416 [View Article][PubMed]
     [Google Scholar]
  22. Pascolo S, Bervas N, Ure JM, Smith AG, Lemonnier FA et al. HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med 1997; 185:2043–2051 [View Article][PubMed]
     [Google Scholar]
  23. Matsui M, Moriya O, Yoshimoto T, Akatsuka T. T-Bet is required for protection against vaccinia virus infection. J Virol 2005; 79:12798–12806 [View Article][PubMed]
     [Google Scholar]
  24. Lutz MB, Kukutsch N, Ogilvie AL, Rössner S, Koch F et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 1999; 223:77–92 [View Article][PubMed]
     [Google Scholar]
  25. Kawano M, Takagi R, Saika K, Matsui M, Matsushita S. Dopamine regulates cytokine secretion during innate and adaptive immune responses. Int Immunol 2018; 30:591–606 [View Article][PubMed]
     [Google Scholar]
  26. Lenz P, Day PM, Pang YY, Frye SA, Jensen PN et al. Papillomavirus-like particles induce acute activation of dendritic cells. J Immunol 2001; 166:5346–5355 [View Article][PubMed]
     [Google Scholar]
  27. Boura E, Liebl D, Spísek R, Fric J, Marek M et al. Polyomavirus EGFP-pseudocapsids: analysis of model particles for introduction of proteins and peptides into mammalian cells. FEBS Lett 2005; 579:6549–6558 [View Article][PubMed]
     [Google Scholar]
  28. Tegerstedt K, Franzén A, Ramqvist T, Dalianis T. Dendritic cells loaded with polyomavirus VP1/VP2Her2 virus-like particles efficiently prevent outgrowth of a HER2/neu expressing tumor. Cancer Immunol Immunother 2007; 56:1335–1344 [View Article][PubMed]
     [Google Scholar]
  29. Ackerman AL, Cresswell P. Cellular mechanisms governing cross-presentation of exogenous antigens. Nat Immunol 2004; 5:678–684 [View Article][PubMed]
     [Google Scholar]
  30. Tsai B, Gilbert JM, Stehle T, Lencer W, Benjamin TL et al. Gangliosides are receptors for murine polyoma virus and SV40. Embo J 2003; 22:4346–4355 [View Article][PubMed]
     [Google Scholar]
  31. Atwood WJ, Norkin LC. Class I major histocompatibility proteins as cell surface receptors for simian virus 40. J Virol 1989; 63:4474–4477 [View Article][PubMed]
     [Google Scholar]
  32. Kartenbeck J, Stukenbrok H, Helenius A. Endocytosis of simian virus 40 into the endoplasmic reticulum. J Cell Biol 1989; 109:2721–2729 [View Article][PubMed]
     [Google Scholar]
  33. Pelkmans L, Kartenbeck J, Helenius A. Caveolar endocytosis of simian virus 40 reveals a new two-step vesicular-transport pathway to the ER. Nat Cell Biol 2001; 3:473–483 [View Article][PubMed]
     [Google Scholar]
  34. Engel S, Heger T, Mancini R, Herzog F, Kartenbeck J et al. Role of endosomes in simian virus 40 entry and infection. J Virol 2011; 85:4198–4211 [View Article][PubMed]
     [Google Scholar]
  35. Kuraoka M, Snowden PB, Nojima T, Verkoczy L, Haynes BF et al. Bcr and endosomal TLR signals synergize to increase aid expression and establish central B cell tolerance. Cell Rep 2017; 18:1627–1635 [View Article][PubMed]
     [Google Scholar]
  36. Perrin-Cocon LA, Villiers CL, Salamero J, Gabert F, Marche PN. B cell receptors and complement receptors target the antigen to distinct intracellular compartments. J Immunol 2004; 172:3564–3572 [View Article][PubMed]
     [Google Scholar]
  37. Chen XS, Garcea RL, Goldberg I, Casini G, Harrison SC. Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol Cell 2000; 5:557–567 [View Article][PubMed]
     [Google Scholar]
  38. Wen Y-M, Mu L, Shi Y. Immunoregulatory functions of immune complexes in vaccine and therapy. EMBO Mol Med 2016; 8:1120–1133 [View Article][PubMed]
     [Google Scholar]
  39. Bournazos S, Ravetch JV. Fcγ receptor function and the design of vaccination strategies. Immunity 2017; 47:224–233 [View Article][PubMed]
     [Google Scholar]
  40. Bouige P, Iscaki S, Cosson A, Pillot J. Molecular analysis of the modulatory factors of the response to HBsAg in mice as an approach to HBV vaccine enhancement. FEMS Immunol Med Microbiol 1996; 13:71–79 [View Article][PubMed]
     [Google Scholar]
  41. Bouige P, Iscaki S, Pillot J. Immune complexes as immunizing agents to increase the number of monoclonal antibody producing hybrids and to deviate the response to poorly immunogenic epitopes. Hybridoma 1990; 9:519–526 [View Article][PubMed]
     [Google Scholar]
  42. Haddad EE, Whitfill CE, Avakian AP, Ricks CA, Andrews PD et al. Efficacy of a novel infectious bursal disease virus immune complex vaccine in broiler chickens. Avian Dis 1997; 41:882–889 [View Article][PubMed]
     [Google Scholar]
  43. Hioe CE, Visciano ML, Kumar R, Liu J, Mack EA et al. The use of immune complex vaccines to enhance antibody responses against neutralizing epitopes on HIV-1 envelope gp120. Vaccine 2009; 28:352–360 [View Article][PubMed]
     [Google Scholar]
  44. Kumar R, Tuen M, Li H, Tse DB, Hioe CE. Improving immunogenicity of HIV-1 envelope gp120 by glycan removal and immune complex formation. Vaccine 2011; 29:9064–9074 [View Article][PubMed]
     [Google Scholar]
  45. Kumar R, Tuen M, Liu J, Nàdas A, Pan R et al. Elicitation of broadly reactive antibodies against glycan-modulated neutralizing V3 epitopes of HIV-1 by immune complex vaccines. Vaccine 2013; 31:5413–5421 [View Article][PubMed]
     [Google Scholar]
  46. Pokrić B, Sladić D, Juros S, Cajavec S. Application of the immune complex for immune protection against viral disease. Vaccine 1993; 11:655–659 [View Article][PubMed]
     [Google Scholar]
  47. Visciano ML, Tuen M, Chen P-de, Hioe CE. Antibodies to the CD4-binding site of HIV-1 gp120 suppress gp120-specific CD4 T cell response while enhancing antibody response. Infect Agent Cancer 2008; 3:11 [View Article][PubMed]
     [Google Scholar]
  48. Xu D-Z, Huang K-L, Zhao K, Xu L-F, Shi N et al. Vaccination with recombinant HBsAg-HBIG complex in healthy adults. Vaccine 2005; 23:2658–2664 [View Article][PubMed]
     [Google Scholar]
  49. Xu D-Z, Wang X-Y, Shen X-L, Gong G-Z, Ren H et al. Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings. J Hepatol 2013; 59:450–456 [View Article][PubMed]
     [Google Scholar]
  50. Yao X, Zheng B, Zhou J, Xu D-Z, Zhao K et al. Therapeutic effect of hepatitis B surface antigen-antibody complex is associated with cytolytic and non-cytolytic immune responses in hepatitis B patients. Vaccine 2007; 25:1771–1779 [View Article][PubMed]
     [Google Scholar]
  51. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 2008; 8:34–47 [View Article][PubMed]
     [Google Scholar]
  52. Da Silva DM, Pastrana DV, Schiller JT, Kast WM. Effect of preexisting neutralizing antibodies on the anti-tumor immune response induced by chimeric human papillomavirus virus-like particle vaccines. Virology 2001; 290:350–360 [View Article][PubMed]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.001445
Loading
Induction of adaptive immune responses against antigens incorporated within the capsid of simian virus 40
J. Gen. Virol. 101, 853 (2020); https://doi.org/10.1099/jgv.0.001445
/content/journal/jgv/10.1099/jgv.0.001445
/content/journal/jgv/10.1099/jgv.0.001445
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error